All posts from Zacks
Zacks in Our Research. Your Success.,

What's in Store for TrovaGene (TROV) this Earnings Season?

TrovaGene Inc. TROV is expected to release first-quarter 2016 results on May 3. Last quarter, the company reported a loss of 27 cents per share, which was narrower than the Zacks Consensus Estimate by a couple of cents.

Notably, the company’s results compared unfavorably with the Zacks Consensus Estimate in the last four quarters, with an average miss of 11.6%.

Let's see how things are shaping up for this quarter.

Factors at Play

We believe that the company’s quarterly results will depend on the adoption rate of its Precision Cancer Monitoring (PCM) technology. As demonstrated by the results from the different ongoing clinical studies, PCM’s superiority in detecting ctDNA in urine samples as compared to traditional procedures is a major attraction for oncologists.

We also note that TrovaGene’s pilot commercial program was well met by oncologists and generated significant demand in the market. However, the resignation of Matthew Posard, the Company's Chief Commercial Officer, can hurt the momentum.

Nevertheless, the recent agreements with Stratose, Fortified Provider Network, Multiplan, FedMed and America's Choice Provider Network will help TrovaGene achieve better market traction as well as top-line growth.

Meanwhile, it will be interesting to see how the recently appointed Chief Executive officer (CEO) William Welch will guide the company toward profits. Investors will closely scrutinize the first-quarter results and the observations by the management to gain some visibility into the company’s future prospects.

Earnings Whispers

Our proven model does not conclusively show that TrovaGene is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP: TrovaGene has a 0.00% ESP. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 31 cents.

Zacks Rank: TrovaGene carries a Zacks Rank #3, which when combined with a 0.00% ESP makes surprise prediction difficult.

Meanwhile, we caution against stocks with a Zacks Ranks #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Stocks to Consider

Here are a few stocks worth considering that, per our model, have the right combination of elements to post an earnings beat this quarter:

PAREXEL International Corporation PRXL with earnings ESP of +2.25% and a Zacks Rank #1.

Align Technology Inc. ALGN with earnings ESP of +5.13% and a Zacks Rank #1.

Becton, Dickinson and Company BDX with earnings ESP of +2.49% and a Zacks Rank #2.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. blog">Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TROVAGENE INC (TROV): Free Stock Analysis Report
ALIGN TECH INC (ALGN): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
PAREXEL INTL CP (PRXL): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research